http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 김재휘(Kim, Jae-Hwi) (검색결과 96 건)
- 무료
- 기관 내 무료
- 유료
-
김재휘,박준성,정태영,정의상.Jae Hui Kim. M.D.. Chun Sung Park. M.D.. Tae Young Chung. M.D.. Eui Sang Chung. M.D. 대한안과학회 2007 대한안과학회지 Vol.48 No.3
Purpose: To evaluate clinical results of AT-45. Methods: In a prospective study, 24 eyes of 21 patients had phacoemulsification and AT-45 implantation. Clinical data included distance visual acuity, near visual acuity, complication, during the 6-months follow-up period. Results: Result analysis was performed with 22 eyes of 19 patients, except 2 complicated eyes. 6-months after operation, 22 eyes (100%) and 19 eyes (86.4%) were achieved best corrected visual acuity 20/25 and 20/20 or better respectively. 21 eyes (95.4%) and 7 eyes (31.8%) were achieved best distance corrected near visual acuity 20/40 and 20/25 or better respectively. Posterior capsular opacity was developed in 5 eyes (22.7%) and posterior synechia was developed in 1 eye (4.5%). Conclusions: Clinical result of cataract surgery with AT-45 was relatively satisfactory. Long term follow-up is recommended.
-
김재휘,조희윤,김종인,기창원,안병헌,강세웅,Jae Hui Kim,Hee Yoon Cho Jong In Kim Chang Won Kee,Byung Heon Ahn,Se Woong Kang 대한안과학회 2007 대한안과학회지 Vol.48 No.2
Purpose: To evaluate influence of phacoemulsification on the progression of diabetic retinopathy Methods: The medical charts of 82 eyes of 41 patients with nonproliferative diabetic retinopathy (DR) who had unilateral phacoemulsification were retrospectively reviewed. The course of diabetic retinopathy was followed up for more than 2 years. Each stage of DR progression was indicated by a unique score, and a comparison of the progression of DR between operated and non-operated eyes was performed using the devised scoring system. Results: The progression of 82 eyes at a mean follow-up period of 28 months was evaluated. DR progressed more in operated eyes than in non-operated eyes (P=0.006). The progression of proliferative DR in operated eyes (19.5%, 8 eyes) was significantly greater (P=0.029) than in non-operated eyes (2.4%, 2 eyes). Conclusions: Phacoemulsification resulted in a progression of diabetic retinopathy. Careful approach to the cataract patients with diabetic retinopathy would be recommended.
-
김재휘,기창원,Jae Hui Kim,M,D,Changwon Kee,M,D 대한안과학회 2008 대한안과학회지 Vol.49 No.1
`Purpose: To investigate the effect of myopic optical defocus on Humphrey Matrix 30-2 test. Methods: Twenty-nine myopic eyes of 29 patients underwent 2 consecutive tests with the Humphrey Matrix 30-2 threshold program. The first and second tests were performed with and without correction for myopia. Differences between the mean deviation (?MD) and the pattern standard deviation (?PSD) were calculated, and a correlation between the spherical equivalent (SE) and ?MD and ?PSD was investigated. The influence of optical defocus according to the visual field (central and peripheral) and the severity of glaucomatous visual field damage (area with total deviation plot of ‘P<0.1%’ or ‘P<0.5%’ and the other area) were also evaluated. Results: The correlation between SE and ?MD was significant (p=0.02, r=0.62). However, the correlation between SE and ?PSD was not significant (p=0.81, r=0.15). The differences in the mean total deviation printout value of the central and peripheral visual field groups between the two tests were 5.85±4.26dB and 5.66±3.56dB, respectively (P=0.86). The differences in the mean total deviation printout value of severely damaged and less damaged areas between the two tests were 3.16±3.39dB and 6.62±4.62dB, respectively (P<0.01). Conclusions: Myopic optical defocus has a significant effect on the results of the Humphrey Matrix 30-2 test. There is no difference in the effect of myopia between the central and peripheral visual fields, and the effect is decreased in severely damaged visual fields.`
-
김재휘,오동은,김윤덕,Jae Hui Kim,M,D,Dong Eun Oh,M,D,Yoon Duck Kim,M,D 대한안과학회 2007 대한안과학회지 Vol.48 No.4
Purpose: To report a case of primary yolk sac tumor of the orbit. Methods: A 15-month-old girl was referred for evaluation of ptosis and strabismus in the right eye which had developed over the previous two weeks. On examination, ptosis, exotropia, proptosis, and restriction of extraocular muscle movement of the right eye were noted. A computed tomography (CT) scan of the orbit showed a 2.4 cm×3.4 cm-sized soft tissue mass in the posterior aspect of the right orbit which enveloped the optic nerve and invaded the maxillary sinus, posterior ethmoid sinus, nasal cavity, and intracranial space. Endoscopic biopsy of the nasal cavity mass was performed. Results: Histologic evaluation revealed solid proliferation of germ cells with large, clear cytoplasm and intracellular, extracellular hyaline globules. Immunohistochemical staining for alpha-fetoprotein was positive. Results of further systemic evaluation were all negative. The tumor regressed after combined chemotherapy and radiotherapy. The patient has been disease free for 2 years. Conclusions: The possibility of yolk sac tumor should be considered in the differential diagnosis in a younger patient for an orbital mass with rapidly increasing size and adjacent bony destruction. Prompt diagnosis and appropriate therapeutic approaches are essential.
-
조절인공수정체를 이용한 백내장 수술 후 측정한 전방깊이 및 굴절값의 변화
김재휘,박준성,정의상,정태영,Jae Hui Kim,M,D,Chun-Sung Park,M,D,Eui-Sang Chung,M,D,Tae-Young Chung,M,D 대한안과학회 2007 대한안과학회지 Vol.48 No.11
Purpose: To evaluate the change in anterior chamber depth and refraction after AT-45 implantation Methods: Twenty-two eyes from 22 patients were enrolled in this prospective study. After phacoemulsification, AT-45 (11 eyes) and SA60AT (11 eyes) were implanted. Clinical data included anterior chamber depth and refractive error at 1 week, 1 month, 2 months and 6 months postoperatively. The correlation between anterior chamber depth change and spherical equivalent change was also evaluated. Results: In the AT-45 implanted group, the mean anterior chamber depth was 4.56±0.59 mm at 1 week postoperative, 4.70±0.69 mm at 1 month postoperative, 4.78±0.71 mm at 2 months postoperative and 4.76±0.69 mm at 6 months postoperative. The mean spherical equivalent was -0.53±0.48D, -0.37±0.42D, -0.27±0.47D, and -0.33±0.44D respectively. When analyzed using the Mann-Whitney U test, p-values of anterior chamber depth differences between the 2 groups were P=0.52 at 1 week to 1 month, P=0.32 at 1 month to 2 months, P=0.89 at 2 months to 6 months, and P=0.02 at 1 week to 6 months, showing a deeper anterior chamber in the AT-45 implanted group. P-values (Mann-Whitney U test) of spherical equivalent differences between the 2 groups were P=0.33, P=0.56, P=0.94, and P=0.19, respectively, showing more hyperopic change in the AT-45 implanted group. The correlation between anterior chamber depth change and spherical equivalent change in the AT-45 implanted group at 1 week to 6 months was not statistically significant (Spearman correlation analysis, P=0.223). Conclusions: Anterior chamber depth deepening and associated hyperopic refractive change were observed after AT-45 implantation, especially at 1 month after the surgery.
-
-
-
망막혈관종성증식에서 유리체강내 라니비주맙과 애플리버셉트 주입술의 단기 임상결과 비교
김오제(Oh Jae Kim),김재휘(Jae Hui Kim),김종우(Jong Woo Kim),이태곤(Tae Gon Lee),조성원(Sung Won Cho),이동원(Dong Won Lee),한정일(Jung Il Han),김철구(Chul Gu Kim) 대한안과학회 2016 대한안과학회지 Vol.57 No.2
목적: 망막혈관종성증식에서 유리체강내 라니비주맙과 애플리버셉트 주입술을 이용하여 치료한 6개월의 임상 결과를 보고하고자 한다. 대상과 방법: 망막혈관종성증식으로 진단 후 유리체강내 라니비주맙 혹은 애플리버셉트 주입술로 치료 받은 31안(28명)을 대상으로 후향적 의무기록 분석을 시행하였다. 진단 후 1개월 간격으로 3회의 주사 후, 이후에는 재발하는 경우 추가 치료를 시행하였다. 치료전 및 첫 번째 주사 후 3, 6개월에 최대교정시력 및 중심망막두께를 측정하여 비교하였다. 결과: 라니비주맙군은 16안, 애플리버셉트군은 15안이었다. 치료 전 및 치료 후 3개월, 6개월에 측정된 평균 최대교정시력(logMAR)은 라니비주맙군에서 0.78 ± 0.50, 0.47 ± 0.30, 0.59 ± 0.41, 애플리버셉트군에서 0.96 ± 0.52, 0.83 ± 0.52, 0.74 ± 0.56이고, 평균 중심망막두께는 라니비주맙군에서 315.75 ± 115.44, 188.38 ± 57.33, 218.50 ± 96.49 μm, 애플리버셉트군에서 249.00 ± 74.88, 143.73 ± 32.73, 196.73 ± 94.08 μm였다. 두 군 모두에서 진단 후 6개월에 측정된 최대교정시력은 진단 당시와 비교하여 유의하게 호전되었으며(p<0.05), 중심망막두께 역시 유의하게 감소하였다(p<0.05). 두 군 사이에 시력(p=0.770) 및 중심망막두께 (p=0.470)의 감소 정도는 유의한 차이가 없었다. 결론: 유리체강내 라니비주맙 혹은 애플리버셉트 주입술은 망막혈관종성증식 환자에서 시력을 호전시키고 황반두께를 정상화시키는데 효과적인 방법으로 생각된다. Purpose: To evaluate the 6-month outcomes of intravitreal ranibizumab and aflibercept treatment for patients with retinal angiomatous proliferation (RAP). Methods: A retrospective review of medical records of 28 patients (31 eyes) diagnosed with RAP was performed. All patients were initially treated with 3 consecutive intravitreal ranibizumab or aflibercept injections after diagnosis. Additional treatment was performed when exudation recurred. The best-corrected visual acuity (BCVA) and central foveal thickness were measured before the first injection and 3 and 6 months after the first injection. The values measured before the treatment were compared with those after treatment. Results: Sixteen eyes were treated with ranibizumab and 15 eyes with aflibercept. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and 3 and 6 months after the first injection were 0.78 ± 0.50, 0.47 ± 0.30 and 0.59 ± 0.41 in the ranibizumab group and 0.96 ± 0.52, 0.83 ± 0.52 and 0.74 ± 0.56 in the aflibercept group, respectively. Central foveal thickness was 315.75 ± 115.44, 188.38 ± 57.33 and 218.50 ± 96.49 μm in the ranibizumab group and 249.00 ± 74.88, 143.73 ± 32.73 and 196.73 ± 94.08 μm in the aflibercept group, respectively. BCVA was significantly improved and central foveal thickness was significantly reduced at 6 months (p < 0.05) compared to measurements before the first injection in both groups. However, BCVA improvement and central foveal thickness were not significantly different between the 2 groups. Conclusions: Both intravitreal ranibizumab and aflibercept treatments were beneficial for both normalizing macular thickness and improving visual acuity in patients with RAP. The efficacy of the 2 drugs was not noticeably different.
-
라니비주맙 치료에 반응이 제한적인 습성황반변성에서 3회 애플리버셉트 주입술의 효과
김경민(Kyung Min Kim),김재휘(Jae Hui Kim),장영석(Young Suk Chang),김종우(Jong Woo Kim),김철구(Chul Gu Kim),이동원(Dong Won Lee) 대한안과학회 2017 대한안과학회지 Vol.58 No.1
Purpose: To evaluate the efficacy of 3 bimonthly aflibercept injections for neovascular age-related macular degeneration (AMD) that showed limited response to 3 initial ranibizumab injections. Methods: Three bimonthly aflibercept injections were performed for 21 eyes with neovascular AMD that was refractory to 3 monthly ranibizumab injections. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured at diagnosis, 1 month after 3 ranibizumab injections, and 1 month after 3 aflibercept injections, and these values were compared. Results: The mean logarithm of minimal angle of resolution (logMAR) BCVA at diagnosis, after ranibizumab therapy, and after aflibercept therapy was 0.62 ± 0.29, 0.73 ± 0.31, and 0.65 ± 0.28, respectively. The CRT at the aforementioned times was 427.0± 98.7 μm, 409.5 ± 78.7 μm, and 315.9 ± 98.2 μm, respectively. When compared with the value measured after ranibizumab therapy, CRT was significantly decreased after aflibercept therapy (p < 0.001), whereas there was no significant difference in BCVA(p = 0.092) between the two times. Improved BCVA was noted in 8 eyes (38.1%) after aflibercept therapy and BCVA was unchanged in 11 eyes (52.4%). Decreased CRT was noted in 18 eyes (85.7%) after aflibercept therapy. Conclusions: Three bimonthly aflibercept injections were found to be useful in terms of improving or maintaining visual acuity, as well as reducing retinal thickness in neovascular AMD that showed limited response to 3 initial ranibizumab injections. 목적: 최초 3회 라니비주맙 주입술에 반응이 제한적인 습성황반변성을 대상으로 한 2개월 간격 3회 애플리버셉트 주입술의 임상 결과를 알아보고자 한다. 대상과 방법: 습성황반변성으로 진단된 후 1개월 간격으로 3회 라니비주맙 주입술을 시행 받았으나 반응이 없어 2개월 간격으로 3회 애플리버셉트 주입술을 추가로 시행 받은 21명의 환자를 대상으로 후향적 의무기록 분석을 시행하였다. 진단 시, 라니비주맙 치료후 1개월 및 애플리버셉트 치료 후 1개월에 측정된 시력과 중심망막두께를 서로 비교하였다. 결과: 최초 진단 시, 라니비주맙 치료 후, 및 애플리버셉트 치료 후 측정된 평균 logarithm of minimal angle of resolution (logMAR) 시력은 각각 0.62 ± 0.29, 0.73 ± 0.31 및 0.65 ± 0.28이었으며, 중심망막두께는 각각 427.0 ± 98.7 μm, 409.5 ± 78.7 μm 및 315.9 ± 98.2 μm였다. 라니비주맙 주입술 후와 비교하였을 때 애플리버셉트 주입술 후 유의한 중심망막두께의 감소가 나타났으나(p<0.001) 시력은 차이가 없었다(p=0.092). 애플리버셉트 주입술 후 시력이 호전된 경우는 8안(38.1%)이었으며, 11안(52.4%)의 경우 시력의 변화가 없었다. 애플리버셉트 주입술 후 18안(85.7%)에서 중심망막두께가 감소하였다. 결론: 최초 3회 라니비주맙 주입술에 반응이 제한적인 환자를 대상으로 한 2개월 간격 3회 애플리버셉트 주입술은 시력을 유지시키거나 호전시키고 망막 두께를 감소시키는 데 유용한 치료 방법으로 생각된다.
-
KCI
스콜라연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
